#United States #Alpharetta #Hyaluronic Acid #Avanos Medical #Channel-Markers

Avanos Medical Completes Sale of Hyaluronic Acid Product Line to Channel-Markers Medical

Avanos Medical, Inc. (NYSE: AVNS) has officially announced its decision to divest its Hyaluronic Acid (HA) product line to Channel-Markers Medical, LLC (CMM), a private entity based in Raleigh, North Carolina. This transition, solidified on July 31, 2025, marks a significant milestone in Avanos’ ongoing strategic transformation, focusing on enhancing its operational segments in Pain Management and Specialty Nutrition Systems.

The divested product portfolio includes the well-known injectable treatments, TriVisc® and GenVisc® 850, specifically designed for alleviating pain associated with osteoarthritis (OA) in the knee. These therapies aim to provide effective symptom management and help patients restore joint functionality.

Dave Pacitti, CEO of Avanos, emphasized the significance of this divestiture in reinforcing the company’s commitment to focused growth. He stated, “This divestiture represents a meaningful step in advancing our transformation strategy and reinforcing our commitment to focused growth. By aligning our product portfolio more closely with our strategic priorities, we expect to strengthen our ability to invest in those areas where we see the greatest potential.” This strategic realignment is designed to enhance Avanos' capacity for innovation and long-term value delivery for patients and partners alike.

Channel-Markers Medical, the acquirer, is known for its focus on joint health, regenerative therapy development, and minimally invasive pain management solutions. By integrating the HA portfolio into its offerings, CMM aims to bolster its presence in musculoskeletal health and injectable pain therapies. David Toledo, managing partner at CMM, expressed enthusiasm about the acquisition, stating, “This acquisition aligns with our mission to deliver high-quality, clinically proven therapies that improve patient mobility and quality of life.”

The ownership transition has been officially executed, with Avanos agreeing to provide transition support until the end of 2025. This is to ensure seamless service continuity for customers, partners, and patients who rely on these important healthcare products.

Avanos Medical, headquartered in Alpharetta, Georgia, is dedicated to designing and delivering clinically superior medical device solutions aimed at helping patients return to their everyday lives. They tackle pressing health concerns, from nutritional needs for patients in recovery to combatting opioid reliance in pain management. In residential and hospital settings alike, Avanos emphasizes innovation and the provision of crucial health solutions.

Channel-Markers Medical, on the other hand, is recognized for its commitment to innovation and enhancing patient access and outcomes in pain management and orthopedic specialties. Their acquisition of Avanos' HA products is likely to enhance their portfolio, providing healthcare professionals and patients with effective tools to manage pain and enhance mobility.

In summary, this divestiture underscores a proactive approach by Avanos to deepen its focus on strategic segments while empowering Channel-Markers Medical to expand its influence in joint health therapies. This transaction is indicative of the evolving landscape of healthcare, emphasizing the importance of tailored solutions in the face of diverse patient needs.

For more information about Avanos Medical, visit www.avanos.com and follow them on social platforms. To learn about Channel-Markers Medical and their innovative solutions, check out www.channel-markers.com.